These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32110202)

  • 21. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma.
    Koizumi Y; Hirooka M; Hiraoka A; Ochi H; Tanaka T; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Miyake T; Matsuura B; Michitaka K; Joko K; Abe M; Hiasa Y
    Endocr J; 2019 Sep; 66(9):787-792. PubMed ID: 31142692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting.
    Obi S; Sato T; Sato S; Kanda M; Tokudome Y; Kojima Y; Suzuki Y; Hosoda K; Kawai T; Kondo Y; Isomura Y; Ohyama H; Nakagomi K; Ashizawa H; Miura Y; Amano H; Mochizuki H; Omata M
    Hepatol Int; 2019 Mar; 13(2):199-204. PubMed ID: 30671808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatocellular Carcinoma: Etiology and Current and Future Drugs.
    Jindal A; Thadi A; Shailubhai K
    J Clin Exp Hepatol; 2019; 9(2):221-232. PubMed ID: 31024205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.
    He XX; Shi LL; Qiu MJ; Li QT; Wang MM; Xiong ZF; Yang SL
    Biochem Biophys Res Commun; 2018 Oct; 504(4):878-884. PubMed ID: 30219235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New Systemic Therapies for Advanced Hepatocellular Carcinoma].
    Kim DY
    Korean J Gastroenterol; 2019 Jan; 73(1):10-15. PubMed ID: 30690953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lenvatinib mesylate to treat hepatocellular carcinoma.
    Ielasi L; Tovoli F; Piscaglia F
    Drugs Today (Barc); 2019 May; 55(5):305-313. PubMed ID: 31131841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis.
    Huang C; Zhu XD; Shen YH; Wu D; Ji Y; Ge NL; Chen LL; Tan CJ; Zhou J; Fan J; Sun HC
    Biomark Res; 2021 Mar; 9(1):19. PubMed ID: 33743822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
    Oikonomopoulos G; Aravind P; Sarker D
    Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma.
    Takinami M; Yokota T
    Case Rep Oncol; 2020; 13(2):522-527. PubMed ID: 32518548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.
    Cabanillas ME; Takahashi S
    Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma.
    Zheng A; Chevalier N; Calderoni M; Dubuis G; Dormond O; Ziros PG; Sykiotis GP; Widmann C
    Oncotarget; 2019 Dec; 10(66):7058-7070. PubMed ID: 31903165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma.
    Trojan J; Waidmann O
    J Hepatocell Carcinoma; 2016; 3():31-36. PubMed ID: 27703962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted agents for second-line treatment of advanced hepatocellular carcinoma.
    Personeni N; Pressiani T; Bozzarelli S; Rimassa L
    World J Gastrointest Oncol; 2019 Oct; 11(10):788-803. PubMed ID: 31662820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
    Ikeda M; Kobayashi M; Tahara M; Kaneko S
    Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field.
    Doycheva I; Thuluvath PJ
    J Clin Exp Hepatol; 2019; 9(5):588-596. PubMed ID: 31695249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib.
    Kimura-Tsuchiya R; Sasaki E; Nakamura I; Suzuki S; Kawana S; Okouchi C; Fukushima T; Hashimoto Y; Suzuki S; Saji S
    Case Rep Oncol; 2018; 11(1):75-80. PubMed ID: 29515414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma.
    Baxter MA; Glen H; Evans TR
    Future Oncol; 2018 Aug; 14(20):2021-2029. PubMed ID: 29783903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor.
    Hussein Z; Mizuo H; Hayato S; Namiki M; Shumaker R
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):903-914. PubMed ID: 28236116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatic encephalopathy induced by Lenvatinib and anti-PD-1 mAb in a patient with advanced hepatocellular carcinoma: A case report.
    Liu Z; Meng Y; Xiao W; Wang H; Sun L; Fu Z; Xiong X; Zhang S
    Mol Clin Oncol; 2021 Jun; 14(6):110. PubMed ID: 33859824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.